Metoclopramide

證據等級: L5

預測適應症: 5 個

Metoclopramide: From Nausea and Vomiting to Gastric Ulcer

One-Sentence Summary

Metoclopramide is a dopamine antagonist and prokinetic agent, widely used for treating nausea, vomiting, and gastroparesis by accelerating gastric emptying and coordinating gastrointestinal motility. The TxGNN model predicts it may be effective for Gastric Ulcer, with 2 clinical trials and 20 publications currently supporting this direction. However, the majority of evidence is preclinical or mechanistic, and dedicated clinical confirmation for this specific indication is still lacking.

Quick Overview

Item	Content
Original Indication	Nausea and vomiting; gastroparesis (based on published pharmacology literature)
Predicted New Indication	Gastric Ulcer
TxGNN Prediction Score	99.93%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Formal MOA data is not available in the structured record for this drug. Based on published literature (Albibi & McCallum, Annals of Internal Medicine, 1983), Metoclopramide works through two principal pathways: (1) it antagonizes dopamine D2 receptors in the gastrointestinal tract, strengthening antral contractions and accelerating gastric emptying; and (2) it augments acetylcholine release from enteric neurons while sensitizing smooth muscle to its effects, thereby coordinating gastroduodenal motility. Its central D2 antagonism at the chemoreceptor trigger zone (CTZ) accounts for the well-established antiemetic activity.

The connection to gastric ulcer is mechanistically plausible. When gastric emptying is delayed, acidic contents linger in the stomach longer, prolonging contact with an already-damaged mucosa and impairing healing. By accelerating gastric clearance, Metoclopramide can theoretically shorten this acid exposure window. Equally relevant, it reduces duodenogastric bile reflux — a recognised secondary mechanism of mucosal injury — by improving pyloric and antroduodenal coordination. Two animal studies have confirmed this protective effect directly: in aspirin-induced and pylorus-ligated rat models (PMID 2730234) and in three different guinea pig ulcer models (PMID 6436177), Metoclopramide reduced gastric ulceration without altering acid secretion, pointing to improved drainage and reduced pyloric reflux as the operative mechanism.

It is important to note, however, that this is an adjunctive role. Modern standard of care for gastric ulcer is PPI therapy with or without H. pylori eradication — pathways in which Metoclopramide plays no direct part. Its prokinetic mechanism cannot replace acid suppression or antibacterial treatment. Any clinical adoption as a repurposed agent would need to demonstrate additive healing benefit beyond current standard therapy in a controlled trial.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05746377	Phase 4	Unknown	60	Tests whether pre-endoscopy metoclopramide improves gastric wall visibility and reduces the need for repeat endoscopy, interventional radiology, or surgery in upper GI bleeds (gastric ulcer is a common cause); relevant as an indirect, procedural use rather than direct ulcer treatment
NCT03747107	N/A	Completed	19	Pharmacist-driven prescribing quality improvement programme across NHS Tayside (Scotland); metoclopramide appears as one of many drugs reviewed for safety risks — not a direct intervention trial for gastric ulcer

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2730234	1989	Animal Study (Rat)	Arch Int Pharmacodyn	Metoclopramide (20–50 mg/kg) showed significant ulcer-protective effects in aspirin-induced and pylorus-ligated gastric ulcer models; compared favourably to ranitidine; effect attributed to improved gastric drainage, not acid suppression
6436177	1984	Animal Study (Guinea Pig)	Indian J Physiol Pharmacol	Metoclopramide protected against all three experimental gastric ulceration models without altering gastric acid secretion; mechanism proposed as promotion of gastric drainage and prevention of pyloric reflux
4779253	1973	Clinical Study	Curr Med Res Opinion	Examined metoclopramide’s effect on bile reflux in gastric ulcer patients alongside smoking and carbenoxolone; directly relevant to bile acid–mediated mucosal damage pathway
775822	1976	Clinical Report	ZFA Allgemeinmedizin	Direct clinical case series on the use of metoclopramide in gastric and duodenal ulcer therapy
6336644	1983	Pharmacology Review	Ann Intern Med	Comprehensive review of metoclopramide pharmacology; details D2 antagonism, GI smooth muscle stimulation, and acetylcholine augmentation as the primary mechanisms underpinning its GI effects
19225	1977	Narrative Review	Drugs	Narrative review positioning metoclopramide alongside conventional drugs used in the management of gastric and duodenal ulcer
6106882	1980	Clinical Review	Medizinische Klinik	Conservative treatment strategies for gastric ulcer, including discussion of prokinetic agents as adjuncts
28652516	2017	Animal Study (Rat)	J Smooth Muscle Res	Evaluated the effects of prokinetic drugs including metoclopramide on gastric emptying in acetic acid-induced ulcer rat models; found that ulcer position affects the gastric emptying response to prokinetics
16807979	2006	Clinical RCT	Yonsei Med J	Prospective double-blind RCT (n=40) evaluating IV metoclopramide + ranitidine vs placebo on preoperative gastric content volume and acidity; relevant to understanding Metoclopramide’s effect on gastric secretory environment
11879596	2002	Clinical Review	Curr Treat Options Gastroenterol	Functional dyspepsia review; Metoclopramide discussed as a primary prokinetic option for symptom management with mechanistic overlap relevant to upper GI mucosal conditions

Philippines Market Information

Metoclopramide is currently not registered with the Philippine FDA. No product authorization records are on file. Any clinical use or trial initiation in the Philippines would first require product registration or an appropriate clinical trial import permit.

Safety Considerations

Please refer to the package insert for safety information.

Note from literature: One published case report (PMID 3059051, J SC Med Assoc, 1988) specifically describes neurotoxicity associated with Metoclopramide. As a dopamine D2 antagonist, Metoclopramide carries a well-documented risk of extrapyramidal reactions and — with prolonged use — tardive dyskinesia. This should be factored into any risk-benefit assessment before clinical evaluation of this repurposing candidate.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link between Metoclopramide and gastric ulcer is biologically coherent — improved gastric emptying and reduced bile reflux plausibly support mucosal protection — but the evidence base is limited to animal studies and older pharmacology reviews (Level L4), with no completed clinical trial directly testing this indication. The drug also has no Philippines market registration, making clinical adoption premature at this stage.

To proceed, the following is needed:

A dedicated Phase 2 pilot study testing Metoclopramide as an adjunct to PPI ± H. pylori eradication in gastric ulcer healing outcomes
Formal MOA data retrieval from the DrugBank API to complete the mechanistic profile
Philippine FDA package insert review (or TFDA/EMA label cross-reference) to document key warnings, contraindications, and dosing guidance
Drug-drug interaction data (currently unavailable)
Long-term safety assessment focused on extrapyramidal side effects and tardive dyskinesia risk, which is a class-level concern for D2 antagonists and particularly relevant if extended treatment durations are considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.